Precigen, Inc. (PGEN) Stock Grade

About Precigen, Inc.'s fundamentals

Precigen is a biotechnology company with a market capitalization of $2.8 billion that has demonstrated strong revenue growth of 146.7% year-over-year, indicating significant commercial traction or expansion in its business operations. However, the company reported a substantial net loss in its latest annual statement, reflected in a net margin of -2588.2%, meaning expenses far exceeded revenues. The company does not currently pay a dividend, and traditional profitability metrics like P/E ratio and return on equity are not applicable due to the net loss position. This profile is typical of growth-stage biotech firms that prioritize revenue expansion and research investment over near-term profitability.